Cytokinetics, Incorporated
CYTK · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $18,474 | $7,530 | $94,588 | $70,428 |
| % Growth | 145.3% | -92% | 34.3% | – |
| Cost of Goods Sold | $339,408 | $330,123 | $240,813 | $159,938 |
| Gross Profit | -$320,934 | -$322,593 | -$146,225 | -$89,510 |
| % Margin | -1,737.2% | -4,284.1% | -154.6% | -127.1% |
| R&D Expenses | $339,408 | $330,123 | $240,813 | $159,938 |
| G&A Expenses | $215,314 | $173,612 | $177,977 | $96,803 |
| SG&A Expenses | $215,314 | $173,612 | $177,977 | $96,803 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$339,408 | -$330,123 | -$240,813 | -$159,938 |
| Operating Expenses | $215,314 | $173,612 | $177,977 | $96,803 |
| Operating Income | -$536,248 | -$496,205 | -$324,202 | -$186,313 |
| % Margin | -2,902.7% | -6,589.7% | -342.8% | -264.5% |
| Other Income/Exp. Net | -$53,278 | -$30,039 | -$64,753 | -$29,001 |
| Pre-Tax Income | -$589,526 | -$526,244 | -$388,955 | -$215,314 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$589,526 | -$526,244 | -$388,955 | -$215,314 |
| % Margin | -3,191.1% | -6,988.6% | -411.2% | -305.7% |
| EPS | -5.26 | -5.45 | -4.33 | -2.8 |
| % Growth | 3.5% | -25.9% | -54.6% | – |
| EPS Diluted | -5.26 | -5.45 | -4.33 | -2.8 |
| Weighted Avg Shares Out | 111,979 | 96,524 | 89,825 | 76,886 |
| Weighted Avg Shares Out Dil | 111,979 | 96,524 | 89,825 | 76,886 |
| Supplemental Information | – | – | – | – |
| Interest Income | $51,534 | $27,629 | $11,342 | $331 |
| Interest Expense | $86,512 | $57,668 | $51,156 | $29,332 |
| Depreciation & Amortization | $9,531 | $11,892 | $8,399 | $9,637 |
| EBITDA | -$493,483 | -$456,684 | -$329,400 | -$176,345 |
| % Margin | -2,671.2% | -6,064.9% | -348.2% | -250.4% |